Satellos Bioscience Inc. (TSX:MSCL)

Satellos Bioscience Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	18.7	9.8	40.07	16.65	1.42	3.85
Short-Term Investments	51.21	17.91	8.48	13.22	-	-
Cash & Short-Term Investments	69.91	27.71	48.55	29.88	1.42	3.85
Cash Growth	69.73%	-42.92%	62.49%	2007.15%	-63.21%	583.78%
Accounts Receivable	-	-	-	-	-	0
Other Receivables	0.73	0.37	0.44	0.44	0.19	0.42
Total Trade Receivables	0.73	0.37	0.44	0.44	0.19	0.42
Other Current Assets	4.58	3.8	1.76	0.11	0.04	0.03
Total Current Assets	75.22	31.88	50.74	30.43	1.65	4.31
Net Property, Plant & Equipment	0.01	0.01	0	0.01	0.01	0.01
Other Intangible Assets	-	-	-	2.96	2.89	5.65
Long-Term Investments	-	-	-	0.03	0.03	-
Other Long-Term Assets	-	-	-	-	-	5.65
Total Assets	75.23	31.89	50.75	33.43	4.57	9.96
Accounts Payable	4.56	4.11	3.58	2.74	2.09	1.66
Accrued Expenses	4.56	4.11	3.58	2.74	2.09	1.66
Total Current Liabilities	4.56	4.11	3.58	2.74	2.09	1.66
Total Liabilities	4.56	4.11	3.58	2.74	2.09	1.66
Common Stock	133.88	85.83	78.13	46.73	22.26	22.4
Additional Paid-in Capital	30.22	25.65	27.87	19.83	3.52	1.95
Accumulated Other Comprehensive Income	-1.7	-1.72	-1.74	-0.01	-0.01	-0
Retained Earnings	-91.74	-81.97	-57.1	-35.85	-23.3	-16.05
Shareholders' Equity	70.66	27.78	47.16	30.7	2.48	8.29
Total Liabilities & Equity	75.23	31.89	50.75	33.43	4.57	9.96
Net Cash (Debt)	69.91	27.71	48.55	29.88	1.42	3.85
Net Cash Growth	152.30%	-42.92%	62.49%	2007.15%	-63.21%	-
Net Cash Per Share	4.50	1.90	5.08	4.15	0.48	1.92
Book Value	70.66	27.78	47.16	30.7	2.48	8.29
Book Value Per Share	4.55	1.90	4.93	4.26	0.84	4.13
Tangible Book Value	70.66	27.78	47.16	27.74	-0.4	2.65
Tangible Book Value Per Share	4.55	1.90	4.93	3.85	-0.14	1.32

Updated May 15, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.